{"id":"NCT04106557","sponsor":"Healx AI","briefTitle":"A Study of OV101 in Individuals With Angelman Syndrome (AS)","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of OV101 in Pediatric Individuals With Angelman Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-09-09","primaryCompletion":"2020-11-02","completion":"2020-11-02","firstPosted":"2019-09-27","resultsPosted":"2024-01-08","lastUpdate":"2024-01-08"},"enrollment":104,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Primary Disease or Condition Being Studied: Angelman Syndrome (AS)"],"interventions":[{"type":"DRUG","name":"Gaboxadol","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"OV101 once daily (weight-based dosing) Other Name:Gaboxadol","type":"EXPERIMENTAL"},{"label":"Placebo once daily","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to assess the efficacy and safety of oral OV101 (gaboxadol) in pediatric subjects with Angelman syndrome.","primaryOutcome":{"measure":"Clinical Global Impressions- Improvement in Angelman Syndrome (CGI-I-AS) Rating at 12 Weeks","timeFrame":"12 weeks","effectByArm":[{"arm":"OV101 (Ages 4-12 Years, Inclusive)","deltaMin":1,"sd":null},{"arm":"Placebo","deltaMin":2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":14,"countries":["United States","Australia","Germany","Israel","Netherlands"]},"refs":{"pmids":["37639777"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":47},"commonTop":["Vomiting","Nasopharyngitis","Diarrhea","Seizure","Irritability"]}}